Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Subodh Verma Added: 5 months ago
ESC Congress 2025 - NEWTON-CABG finds evolocumab with regular statin therapy did not improve vein graft patency after coronary artery bypass graft (CABG) surgery in the short-term.Dr Subodh Verma and Dr Lawrence Leiter (University of Toronto, Toronto, CA) join us to discuss findings from NEWTON-CABG CardioLink-5 (NCT03900026). The investigator-initiated multicenter, randomised, placebo-controlled… View more
Research Area(s) / Expertise: Job title: Interventional Cardiologist
DrGasparini is an Interventional Cardiologist atHumanitas Research Hospital, Italy. He is specialized in treatment of complex coronary artery disease, such as chronic total occlusions, saphenous vein grafts, bifurcations, left main disease and in management of complications.He is CTO operator, proctor and educator. He is the Founder and Course Director of the CTO Live Aid event. Dr… View more
Author(s): Harriette Van Spall , Stefan James Added: 1 year ago
ESC Congress 2024 — SWEDEGRAFT does not support the routine use of no-touch vein harvest compared to the standard technique.Dr Harriette Van Spall (McMaster University, CA) sits down with principal investigator Prof Stefan James (Uppsala University, SE) to discuss results of the SWEDEGRAFT trial (NCT03501303; Uppsala University).The SWEDEGRAFT trial is a prospective, binational, multicenter, open… View more
Added: 5 months ago Source:  TCT Conference 2025 Programme Guide
Late-breaking clinical trials and science sessions have been announced for Transcatheter Cardiovascular Therapeutics 2025 conference.The conference is set to take place from 25th to 28th October 2025 at the Moscone Center in San Francisco, CA.Access the full programme here.Late-Breaking Clinical Trials: Session I, in Collaboration with The LancetSunday 26th October, 11:00am – 12:28pm (PDT)One… View more
Author(s): Ari Kramer Added: 9 months ago
Real-world outcomes from the FLEX Vessel Prep (VP) system in arteriovenous fistulae and grafts show good safety results with no serious adverse events at 30 days and a high six-month primary patency rate.Dr Ari Kramer (Spartanburg Medical Centre, Spartanburg, US) joins us to discuss outcomes from the prospective, multi-centre, observational study using the FLEX FIRST AV registry (NCT05616104;… View more